Altered Glucocorticoid Rhythm Attenuates the Ability of a Chronic SSRI to Elevate Forebrain 5-HT: Implications for the Treatment of Depression
- 27 March 2003
- journal article
- research article
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 28 (9) , 1572-1578
- https://doi.org/10.1038/sj.npp.1300201
Abstract
Both glucocorticoids and selective serotonin reuptake inhibitors (SSRIs) alter aspects of 5-HT function including somatodendritic 5-HT1A autoreceptor sensitivity. Many depressed patients prescribed SSRIs have pre-existing flattened diurnal gluococorticoid rhythm. In these patients, interactions between flattened glucocorticoid rhythm and chronic SSRIs, which impact on the SSRI's ability to elevate forebrain 5-HT, may alter clinical efficacy. To address this issue rats underwent implantation of slow-release corticosterone (75 mg pellet s.c.) (to flatten the glucocorticoid rhythm) or sham surgery, and injection of fluoxetine (10 mg/kg/day i.p., 12 days) or vehicle. Using microdialysis in the frontal cortex we found that (21 h after the last injection) extracellular 5-HT was elevated in fluoxetine- or corticosterone-treated animals, but not in those treated with corticosterone plus fluoxetine. In fluoxetine-treated animals, blockade of terminal reuptake by local perfusion of fluoxetine increased 5-HT to the same level as it did in controls, suggesting normal terminal 5-HT release after chronic fluoxetine. However, 5-HT levels following local reuptake blockade in both the corticosterone and corticosterone plus fluoxetine groups were lower than controls, suggesting a corticosterone-induced decrease in terminal release. Finally in fluoxetine, corticosterone, and corticosterone plus fluoxetine groups, there was marked 5-HT1A receptor desensitization, evidenced by attenuation of the decrease in 5-HT release following systemic fluoxetine injection. The data indicate that, despite desensitization of 5-HT1A autoreceptors, concurrent flattened glucocorticoid rhythm compromises the ability of SSRIs to elevate forebrain 5-HT. These findings suggest a potential mechanism for the reduced antidepressant efficacy of SSRIs in those patients with pre-existing glucocorticoid abnormalities.Keywords
This publication has 33 references indexed in Scilit:
- State and trait abnormalities in serotonin function in major depressionThe British Journal of Psychiatry, 2002
- How does pindolol improve antidepressant action?Trends in Pharmacological Sciences, 2001
- Effects of chronic fluoxetine treatment in the presence and absence of (±)pindolol: a microdialysis studyBritish Journal of Pharmacology, 2000
- Serotonin, stress and corticoidsJournal of Psychopharmacology, 2000
- Diurnal Activity and Pulsatility of the Hypothalamus-Pituitary-Adrenal System in Male Depressed Patients and Healthy ControlsJournal of Clinical Endocrinology & Metabolism, 1997
- Role of 5-HT1A receptors in the effects of acute and chronic fluoxetine on extracellular serotonin in the frontal cortexPharmacology Biochemistry and Behavior, 1996
- Role of 5‐HT1Aautoreceptors in the mechanism of action of serotoninergic antidepressant drugs: recent findings from in vivo microdialysis studiesFundamental & Clinical Pharmacology, 1996
- 5-HT1A autoreceptors and the mode of action of selective serotonin reuptake inhibitors (SSRI)Behavioural Brain Research, 1995
- Interaction between a selective 5‐HT1Areceptor antagonist and an SSRI in vivo: effects on 5‐HT cell firing and extracellular 5‐HTBritish Journal of Pharmacology, 1995
- Serotonin and Tryptophan Hydroxylase in Isolated Hypothalamic and Brain Stem Nuclei of Rats Exposed to Acute and Repeated Immobilization StressExperimental and Clinical Endocrinology & Diabetes, 1984